Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects
Launched by TURKU UNIVERSITY HOSPITAL · Aug 21, 2017
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Appendectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The previous APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-60 years
- • CT confirmed uncomplicated or complicated acute appendicitis
- • Ability to give consent to participate in the study
- Exclusion Criteria:
- • Age under 18 years or over 60 years
- • Pregnancy or lactation
- • Allergy to contrast media or iodine
- • Allergy or contraindication to antibiotic therapy
- • Renal insufficiency
- • Metformin medication
- • Severe systemic illness (for example malignancy, medical condition requiring immunosuppressant medication)
- • Inability to co-operate and give informed consent
About Turku University Hospital
Turku University Hospital (TYKS) is a leading academic medical center located in Turku, Finland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key institution within the University of Turku, TYKS integrates cutting-edge medical education with state-of-the-art clinical services, offering a broad spectrum of specialized care. The hospital actively participates in clinical trials, facilitating the translation of scientific discoveries into practical treatments, and enhancing patient outcomes. With a multidisciplinary approach and a focus on collaboration, TYKS aims to contribute significantly to the global medical community through its rigorous research initiatives and commitment to patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, , Finland
Patients applied
Trial Officials
Paulina Salminen, MD, PhD
Principal Investigator
Turku University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials